Pacira Pharma (PCRX) Tops Q2 EPS by 7c
Get Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.27, $0.07 better than the analyst estimate of $0.20. Revenue for the quarter came in at $58.3 million versus the consensus estimate of $61.1 million.
EXPAREL net product revenues were $56.0 million in the first quarter of 2015, compared to $34.4 million in the first quarter of 2014.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Netflix (NFLX) raised to Buy at Needham & Company on revenue upside
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!